GET DAILY SIGNALSValneva SE (VALN): Analyst Targets Suggest Potential +112% Gain to $12
Key Takeaways
- The central target of $12 is the arithmetic mean of the individually verified analyst price targets reviewed for VALN, rounded from roughly $12.20.
- The stock last traded near $5.66, so reaching $12 would require a gain of about 112% — a very large move from current levels.
- Analyst targets span an unusually wide range from about $4.90 to $18.00, reflecting deep disagreement over Valneva's pipeline, particularly its Lyme disease vaccine program.
- The strongest supporting factor is the VLA15 Lyme vaccine partnership with Pfizer and the prospect of regulatory filings, while the biggest risk is the chikungunya vaccine setback and continued operating losses.
- Investors can explore the ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages for deeper context.
- Readers interested in automated market scanning can also explore Trending AI Robots for AI-driven trading ideas.
Analyst Price Targets and Consensus View
Valneva SE is a specialty vaccine company headquartered in France whose American Depositary Shares trade on Nasdaq under the ticker VALN. Because it is a stock with several current, attributable analyst targets, the central target is built directly from those figures rather than a headline consensus. Five individually verified targets were reviewed, ranging from roughly $4.90 to $18.00. Averaging them produces about $12.20, which rounds to a central target of $12. The range is exceptionally wide: Goldman Sachs' Rajan Sharma downgraded the stock to Sell with a $4.90 target in April 2026, while H.C. Wainwright's Brandon Folkes reiterated a Buy with an $18 target in September 2026. Between those extremes sit Jefferies at $15, TD Cowen at $12, and Guggenheim at $11. The dispersion reflects genuinely different views of the same story. Bulls weight the Pfizer-partnered Lyme vaccine (VLA15) toward commercial potential, while cautious analysts focus on the August 2025 suspension of the U.S. chikungunya vaccine (IXCHIQ) license and the company's persistent net losses. Third-party aggregators report a similar mean of roughly $12.25–$12.28, consistent with the calculation used here. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
As of early November 2026, VALN traded near $5.66, toward the lower end of its 52-week range of $4.75 to $12.18. The company has a market capitalization around $540 million and reported trailing twelve-month revenue of roughly $163 million against a net loss near $180 million. Closing the gap to $12 would require upside of about 112%, which is a very large move. Such a move would likely depend less on near-term financial results and more on successful execution of the Lyme vaccine program — including Phase 3 data maturation and regulatory submissions — as well as stabilization or recovery in the chikungunya franchise. At current prices, the market is assigning limited value to pipeline optionality, so any positive regulatory or partnership milestone could drive a meaningful re-rating.
What Could Support a Move Toward the Target
- Lyme vaccine opportunity: Pfizer and Valneva reported topline Phase 3 (VALOR) data for VLA15, with Pfizer planning regulatory submissions. A sizable market and milestone payments could transform the revenue base.
- Improved 2026 guidance: Management guided to total revenues of €155 million to €170 million, supported by product sales of €145 million to €160 million.
- Analyst upgrades and new coverage: TD Cowen initiated coverage with a Buy in August 2026, and H.C. Wainwright reaffirmed a high target in September 2026, suggesting some institutions see value ahead of catalysts.
- Established travel-vaccine franchise: IXIARO and DUKORAL provide recurring, if modest, commercial revenue that funds development.
What Could Prevent the Target From Being Reached
- Chikungunya setback: The voluntary withdrawal of the IXCHIQ BLA after the FDA suspended the license removed a near-term U.S. revenue driver and shook confidence.
- Persistent losses: Negative net income and a deeply negative return on equity limit financial flexibility and force reliance on external capital or partners.
- Execution and regulatory risk: The Lyme program is not yet approved, and setbacks or delays would pressure the stock, which already carries a high beta of roughly 1.45.
- Very low liquidity: Trading volume is thin, which can amplify price swings in both directions and complicate large positions.
Technical Levels and Market Structure
The stock sits about $0.90 above its 52-week low of $4.75, a level that acts as a key support zone. Recent trading has consolidated around $5.30–$5.66, with near-term resistance near the $6 area. More durable resistance lies at the psychological $10 level and then the 52-week high of $12.18 — almost exactly the central target. In practical terms, reaching $12 would mean reclaiming the stock's prior high and reversing a prolonged downtrend, a technically demanding feat without a decisive fundamental catalyst. From what I see, the technical setup reinforces how much of a catalyst-driven re-rating would be needed.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though firms rarely state a fixed date and horizons can differ. The most important near-term event is Valneva's next earnings release, scheduled for late November 2026, which may update 2026 guidance and commentary on the Lyme and chikungunya programs. Investors should also watch for Lyme vaccine regulatory submissions by Pfizer, any chikungunya regulatory developments, partnership or financing announcements, and analyst target revisions, which have been frequent given the stock's volatility. Macroeconomic factors such as interest rates and risk appetite for pre-revenue biotech also matter for a small-cap vaccine developer. I'm watching this closely ahead of the upcoming earnings.
Exploring AI Daily Buy/Sell Signals
In my own research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get an additional perspective on momentum shifts for names like this. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It helps me scan for changes in volatile names like VALN more efficiently than manual review allows, complementing the fundamental work on pipeline catalysts and analyst targets.
Final Assessment
The question of whether Valneva SE can reach $12 is really a question about whether its pipeline value will be recognized. The $12 central target, derived from an average of five analyst targets spanning $4.90 to $18.00, implies a very large gain of roughly 112% from the recent price near $5.66. Support rests on the Lyme vaccine program and stabilizing revenue, while the obstacles include the chikungunya setback, ongoing losses, thin liquidity, and heavy technical overhead near the prior 52-week high. The wide analyst spread underscores genuine uncertainty rather than a clear directional signal. Investors should focus on upcoming earnings, Lyme regulatory milestones, and analyst revisions, while keeping in mind that analyst targets are estimates, not guarantees.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VALN sees its Stochastic Oscillator recovers from oversold territory
On October 28, 2026, the Stochastic Oscillator for VALN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In 58 of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VALN's RSI Oscillator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on VALN as a result. In 73 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for VALN just turned positive on October 28, 2026. Looking at past instances where VALN's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +2.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where VALN advanced for three days, in 171 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
VALN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for VALN crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VALN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for VALN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. VALN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.441) is normal, around the industry mean (3.498). P/E Ratio (-3.061) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.559) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VALN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology